CN110290780A - 使用小檗碱纳米颗粒的免疫疾病治疗 - Google Patents

使用小檗碱纳米颗粒的免疫疾病治疗 Download PDF

Info

Publication number
CN110290780A
CN110290780A CN201780077346.3A CN201780077346A CN110290780A CN 110290780 A CN110290780 A CN 110290780A CN 201780077346 A CN201780077346 A CN 201780077346A CN 110290780 A CN110290780 A CN 110290780A
Authority
CN
China
Prior art keywords
berberine
nanoparticles
composition
administered
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780077346.3A
Other languages
English (en)
Chinese (zh)
Inventor
李秀敏
刘长达
K·斯瑞瓦塔瓦
于海琼
S·N·帕克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sean Parker Foundation
Xi Naishanyikan Medical College
Original Assignee
Sean Parker Foundation
Xi Naishanyikan Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sean Parker Foundation, Xi Naishanyikan Medical College filed Critical Sean Parker Foundation
Publication of CN110290780A publication Critical patent/CN110290780A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Composite Materials (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780077346.3A 2016-10-14 2017-10-16 使用小檗碱纳米颗粒的免疫疾病治疗 Pending CN110290780A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408541P 2016-10-14 2016-10-14
US62/408,541 2016-10-14
PCT/US2017/056822 WO2018071917A1 (en) 2016-10-14 2017-10-16 Treatment of immunological disease using berberine nanoparticles

Publications (1)

Publication Number Publication Date
CN110290780A true CN110290780A (zh) 2019-09-27

Family

ID=61906052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780077346.3A Pending CN110290780A (zh) 2016-10-14 2017-10-16 使用小檗碱纳米颗粒的免疫疾病治疗

Country Status (7)

Country Link
US (1) US11351157B2 (https=)
EP (1) EP3525760A4 (https=)
JP (1) JP2019531352A (https=)
CN (1) CN110290780A (https=)
AU (1) AU2017342558A1 (https=)
CA (1) CA3039587A1 (https=)
WO (1) WO2018071917A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116056727A (zh) * 2020-06-11 2023-05-02 纽约市哥伦比亚大学理事会 用于用小檗科生物碱小檗碱及其衍生物预防和治疗近视的方法和组合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3162040A1 (en) * 2019-12-23 2021-07-01 Bronwyn POLLOCK Pharmaceutical compositions
CN114487444B (zh) * 2021-12-28 2024-09-20 上海睿康生物科技有限公司 一种测定血清中抗穆勒氏管激素含量的检测试剂盒
CN114460301B (zh) * 2021-12-28 2024-11-29 上海睿康生物科技有限公司 一种测定血清中肌酸激酶同工酶含量的检测试剂盒
CN114306640A (zh) * 2022-01-27 2022-04-12 南方医科大学南方医院 一种增加小檗碱溶解度的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160175291A1 (en) * 2014-09-17 2016-06-23 Xiu-Min Li Supression of ige production by compounds derived from traditional chinese medicine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254078A1 (en) * 2005-09-16 2008-10-16 Peter Kauper Chitosan-Based Particles
EP1774971A1 (en) 2005-10-14 2007-04-18 Advanced in Vitro Cell Technologies, S.L. Chitosan and heparin nanoparticles
EP1973608A1 (en) * 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US8802076B2 (en) * 2010-10-04 2014-08-12 Duke University Compositions and methods for modulating an immune response
CN105188741A (zh) * 2013-04-03 2015-12-23 阿勒丁医疗公司 新型纳米颗粒组合物
US20160067241A1 (en) * 2013-06-13 2016-03-10 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
US9572831B2 (en) 2013-10-29 2017-02-21 Shaker A. Mousa Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160175291A1 (en) * 2014-09-17 2016-06-23 Xiu-Min Li Supression of ige production by compounds derived from traditional chinese medicine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIUNG-HUNG CHANG等: "Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori", 《ACTA BIOMATERIALIA》 *
SHAO-JUNG WU等: "Delivery of Berberine Using Chitosan/Fucoidan-Taurine Conjugate Nanoparticles for Treatment of Defective Intestinal Epithelial Tight Junction Barrier", 《MAR. DRUGS》 *
李兆申: "《胃黏膜损伤与保护：基础与临床》", 30 April 2004, 上海科学技术出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116056727A (zh) * 2020-06-11 2023-05-02 纽约市哥伦比亚大学理事会 用于用小檗科生物碱小檗碱及其衍生物预防和治疗近视的方法和组合物

Also Published As

Publication number Publication date
EP3525760A1 (en) 2019-08-21
AU2017342558A1 (en) 2019-05-16
WO2018071917A1 (en) 2018-04-19
JP2019531352A (ja) 2019-10-31
US11351157B2 (en) 2022-06-07
CA3039587A1 (en) 2018-04-19
US20200276172A1 (en) 2020-09-03
EP3525760A4 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
JP7368661B2 (ja) 医薬組成物
JP7372897B2 (ja) 改善された粘膜輸送を示す医薬用ナノ粒子
CN110290780A (zh) 使用小檗碱纳米颗粒的免疫疾病治疗
CN106061261B (zh) 治疗化合物的结晶形式及其用途
US12115246B2 (en) Compositions and methods for ophthalmic and/or other applications
US10864219B2 (en) Compositions and methods for ophthalmic and/or other applications
EP4395761A1 (en) Allergy treatment
HK40037930A (en) Pharmaceutical nanoparticles showing improved mucosal transport
WO2015064398A1 (ja) 抗原処理及び処理抗原の利用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190927

WD01 Invention patent application deemed withdrawn after publication